Veltuzumab

DB05656InvestigationalProtein Based Therapies

Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

Protein structure of Veltuzumab
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in lymphoma (non-hodgkin's).Curator reviewed
Formula / weight
C6458H9918N1706O2026S46
Code names
hA20 · IMMU-106

Resolves to

Compound
UNIIBPD4DGQ314CAS728917-18-8
Targets
P11836MS4A1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
421Drug interactionsStructured to mechanism, not free text
Sign in
9Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Veltuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In